Revolutionizing healthcare one cell at a time.

IncellDx is a molecular diagnostics company dedicated to revolutionizing healthcare one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, we focus on critical life threatening diseases such as HIV/AIDs, HPV/Cervical Cancer, Hepatitis, organ transplant infections, breast cancer and ovarian cancer.

Our proprietary diagnostic method provides specific molecular details about each and every cell. This technology now made available through IncellDx, is capable of revolutionizing the field of molecular diagnostics, one cell at a time.

Learn More

NEW: Research article on PLOS One: ‘mRNA and DNA Detection of Human Papillomaviruses in Women of All Ages Attending Two Colposcopy Clinics‘.*
*HPV OncoTect® is CE-IVD marked; product is available for RUO in the US.
Download PDF.

Read our editorial in Future Virology on the utility of our HIV Viral Reservoirs Assay: http://www.futuremedicine.com/doi/full/10.2217/fvl.12.72 as well as our recent HIV Viral Reservoir research publication referenced in our HIV/AIDS literature citing work using the HIV Viral Reservoir Assay: http://incelldx.com/products/literature/

IncellDx Receives the 2012 North American Product Leadership Award in the Molecular Diagnostics Market from Frost & Sullivan

IncellDx Presents First Study Using Their Novel OncoBreast 3Dx™ Breast Cancer Technology

IncellDx scientists presented data using IncellDx’s proprietary OncoBreast 3Dx™ technology to multiplex protein markers for tumor type (E-cadherin) and ER status, markers for her-2 neu protein and mRNA as well as DNA cell cycle and ploidy, all in intact tumor cells in suspension.
Read more: IncellDx Presents First Study Using Their Novel OncoBreast 3Dx™ Breast Cancer Technology

IncellDx Receives North American Product Leadership Award in the Molecular Diagnostics Market

Frost & Sullivan presented IncellDx with a Leadership Award in the Molecular Diagnostics Market.  F&S cited IncellDx’s newly available cervical cancer testing methodology, HPV OncoTect®, as the company’s “greatest contribution” and the “gold standard for gynecological care.”
Read more: IncellDx receives leadership award in molecular diagnostics

BRLI  Announces IncellDx Investment and Launch of GenCerv Through its GenPath Women’s Health Laboratory

BioReference Laboratories, Inc. announced today that it has completed an equity investment in IncellDx, Inc.  In addition, BRLI’s GenPath Women’s Health has launched a new test called GenCerv, based on IncellDx’s patented and proprietary HPV mRNA quantification technology.
Read more: BRLI GenCerv Press Release